Resumen

TUB-CHAFER, Fabiana et al. Activity adjuvant of Bacillus subtilis spores for mucosal route. Vaccimonitor [online]. 2016, vol.25, n.1. ISSN 1025-028X.

Bacillus subtilis spores generally considered safe, have received growing attention due to their potential biotechnological applications including vaccine formulations, particularly as vaccine adjuvants. In the present review we present the status of the adjuvanticity of the spore B. subtilis for mucosal route and our experience regarding its adjuvant activity induced against two model antigens, Tetanus Toxoid (TT) and ovalbumin (Ova) for oral (o.r) and intranasal (i.n) immunization. A document review on B. subtilis, adjuvant, vaccine and mucosal route was carried out in MEDLINE by PubMed, SciELO and LILACS databases. B. subtilis spores (RG 4365) were used for the exploration of the adjuvant activity. Balb/c mice were immunized by i.n and o.r route with TT or Ova combined with B. subtilis spores and specific antibody response in serum, saliva and fecal were measured by ELISA. This review showed the existence of several papers using B. subtilis spores as adjuvant by different methodologies and administration routes, being the expression of recombinant antigens and the the o.r route the most widely used. In our work we found an increase of seric response of IgG, subclass IgG1 and IgG2a and specific IgA in saliva and feces in groups immunized with spores coadministered with Ova and TT by both routes, which was significantly superior to control groups (p<0.05). These data suggest that spores are an efficient mucosal and systemic adjuvant for enhancing humoral immune responses and highlight their clinical potential for future mucosal vaccines.

Palabras clave : Bacillus subtilis; adjuvants; vaccine; mucosal route.

        · resumen en Español     · texto en Español     · Español ( pdf )